Worth Watching Stocks - Winning Brands, AMARANTUS BIOSCI, TRANZBYTE CORPORATIO, Advaxis (OTC:ADXS)

Lakeland, FL -- (SBWIRE) -- 02/26/2013 -- Penny Stock Divas is composed of a team of market professionals consisting of research analysts, technical chartists and traders. With over 50 years of combined experience, we work diligently to provide you with accurate information on our best penny stock picks.

Winning Brands Corporation (PINK:WNBD) stock is at $0.0001,down -50.00 percent. Its today’s volume is 72.60 million shares in comparison to its usual trading volume of 19.32 million shares. The stock opened the session at $0.0002 and touched its highest price point at $0.0002. WNBD lowest price point for the session stood at $0.0001, and its 52 week price range stood at $0.0001 - $0.0006. The company total market capitalization is $868,200. Its beta value stands at 2.72 times.WNBD’s quarterly performance remained red with the percentage of -50, while its year to date performance showed that the stock plunged overall -66.67%. Winning Brands Corporation, through its subsidiary, Niagara Mist Marketing Ltd., designs, manufactures, and sells household and commercial cleaning products, as well as cosmetic and personal care formulations primarily in the United States, Canada, and internationally.

Why Should Investors Buy WNBD After the Recent Fall? Just Go Here and Find Out

AMARANTUS BIOSCI INC (OTC:AMBS) It opened the session at $0.07 and remained in $0.06 and $0.07 price range during the session. The stock is -4.23 percent lowerat $0.0680. Volume closed the day at 4.02 million shares, its average volume being 9.81 million shares.The company total market capitalization is $15.92 million. Its beta value stands at -107.89 times and earnings per share was $-0.02.

Will AMBS Get Buyers Even After The Recent Rally? Find Out Here

AMBS was a loser in the 5 days activity and slipped about -18.66%. The one month performance of stock was negative and it plunged more than -26.09. AmarantusBioScience, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, and Banyan Biomarkers, the leader in developing in vitrodiagnostic products to detect TBI, reported that the companies will be making a joint poster presentation March 6-7, 2013 at The 3rd Annual Traumatic Brain Injury (TBI) Conference in Washington, DC. The poster is entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) neuroprotection from necrotic and apoptotic cell death in rat cortical cultures."

TRANZBYTE CORPORATIO (PINK:ERBB)traded in the range of $0.01 and $0.01 in its previous trading session. The stock recorded the volume of 58.90 million shares so far, in comparison its average daily trading volume of 85.68 million shares. The company total market capitalization is $5.79 million.

Company’s year to date performance remained quiet optimistic with the rise of 268%. If we look at last 6 months of trade that is in bullish zone with an increase of 360%

The stock opened at $0.01 and its closing price for the day was $0.0092, up2.22 percent from its previous close of $0.01. The beta of the ERBB stands at 2.20. 52 week range of the stock is $0.0008 -$0.0193.

What was the Moving Force behind ERBB on Bullish Run? Read This Research Report on ERBB

Advaxis, Inc. (OTC:ADXS) experienced a plungeof -10.77%. After opening the day at $0.14 per share, volume surged to 5.63 million, less than itsaverage volume of 6.64 million shares. Beta value for the Company stands at 1.85, indicating its risk level. The stock remained in $0.12 and $0.14 price range during the session

Company’sgraphical value indicates these stories about the stocks:

During last 5 trades the stock jumped almost 3.57%. During last one month it rose with the percentage of 73.13. Its year to date performance remained progressive with 286.67%.

Stock touched its 52 week highest price point at $0.16. ADXS stock’slowest price point for 52 weeks stood at $0.03.Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the Brown University Oncology Research Group (BrUOG) will be coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer. Dr. Howard Safran, professor of medicine, will be principal investigator. Patients will be treated at Rhode Island Hospital and The Miriam Hospital (the main teaching hospitals of The Warren Alpert Medical School of Brown University). Multiple institutions will collaborate.

Why Should Investors Buy ADXS After the Recent Fall? Just Go Here and Find Out

About Penny Stock Divas
PSD is composed of a team of market professionals consisting of research analysts, technical chartists and traders. With over 50 years of combined experience, we work diligently to provide you with accurate information on our penny stock picks. We use social media tools such as Twitter and Facebook, enabling you to receive time sensitive information in a real-time manner. When you sign up for our FREE penny stock newsletter, you will receive our latest hot penny stock alerts! We have new investment ideas for penny stocks with research and commentary in the penny stock market.

Disclaimer
PSD is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and the company website, but this should not be construed as a recommendation to buy or sell.